Abbvie Inc
NYSE: ABBV
$211.77
+$0.22 (+0.1%)
Closing Price on March 14, 2025
ABBV Articles
The October 15 short interest data have been compared with the previous figures, and for most of the selected pharmaceutical stocks, short interest was mixed.
Published:
Each week we cover the new value calls from the analysts at Jefferies, and more and more, some of the calls may look surprising.
Published:
These biotech stocks 24/7 Wall St. has picked stood out from the rest with at least 25% gains over the course of the past week.
Published:
Friday's top analyst upgrades, downgrades and initiations include AbbVie, Alphabet, Amazon.com, American Electric Power, Apple, Microsoft, Pandora Media and McDonald's.
Published:
ThinkstockThe U.S. Food and Drug Administration (FDA) issued a warning that hepatitis C treatments, Viekira Pak and Technivie, can cause serious liver injury mostly in patients with underlying...
Published:
Last Updated:
These Jefferies Franchise picks with solid dividends are perfect for long-term accounts that like to employ a buy-and-hold strategy.
Published:
The September 30 short interest data have been compared with the previous figures, and for most of the selected pharmaceutical stocks, short interest was mixed.
Published:
Credit Suisse is adding some top conservative dividend-paying stocks to its Top Picks list, and that is right in line with what other top Wall Street firms are doing.
Published:
The September 15 short interest data have been compared with the previous figures, and for most of the selected pharmaceutical stocks, short interest has increased.
Published:
The short interest data have been released for the August 31 settlement date, and for the selected pharmaceutical stocks, short interest is mixed.
Published:
ThinkstockAbbVie Inc. (NYSE: ABBV) has continued to push forward over the past year and shares are actually up 7.3% in the past 52-weeks despite the markets pulling back in August. Late Thursday, the...
Published:
Last Updated:
The August 14 short interest data have been compared with the previous figures, and for the selected pharmaceutical stocks, short interest is mixed.
Published:
ThinkstockWith a very nervous market, and the end of summer doldrums upon us, it may be time to look for ideas that will make sense when the market heats back up in the fall. One area that looks very...
Published:
The short interest data have been released for the July 31 settlement date, and for most of the selected pharmaceutical stocks, short interest decreased.
Published:
Independent research firm Argus has maintained its Buy rating and its $85.00 price target on AbbVie.
Published:
Our expert who first called NVIDIA in 2009 is predicting 2025 will see a historic AI breakthrough.
You can follow him investing $500,000 of his own money on our top AI stocks for free.